eisai to present latest data on perampanel at the 74th american epilepsy society annual meeting
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (aed) perampanel (product name: fycompa®), at the 74th american epilepsy society annual meeting (aes2020), to be held virtually from december 4 to 8, 2020.